LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Listă Acțiuni・Merck & Co Inc.

Merck & Co Inc.

Închisă

Sector Sănătate

117.82 -0.52

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

117.67

Maxim

118.19

Indicatori cheie
By Trading Economics
Venit	693M 5.5B
Vânzări	310M 16B
P/E Medie Sector	137.56 103.001
EPS	2.28
Marjă de profit	33.861
Angajați	72,000
EBITDA	491M 7.4B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+18.88 upside

Dividende
By Dow Jones
Următoarele câștiguri	31 oct. 2024
Data viitoare de dividende	7 oct. 2024
Următoarea dată ex-dividende	16 sept. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	1.8B 300B
Deschiderea anterioară	118.34
Închiderea anterioară	117.82

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

116.6 / 118.395 Suport & Rezistență

Merck & Co Inc. Grafic

Știri relevante

9 aug. 2024, 11:14 UTC

Achiziții, Fuziuni, Preluări

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30 iul. 2024, 14:00 UTC

Câștiguri

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30 iul. 2024, 11:17 UTC

Câștiguri

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

3 sept. 2024, 17:22 UTC

Top știri

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12 aug. 2024, 14:30 UTC

Achiziții, Fuziuni, Preluări

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 aug. 2024, 09:30 UTC

Top știri

Achiziții, Fuziuni, Preluări

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 aug. 2024, 15:56 UTC

Câștiguri

Merck Created the World's Biggest Drug. Now It -2-

1 aug. 2024, 15:56 UTC

Câștiguri

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30 iul. 2024, 15:53 UTC

Câștiguri

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30 iul. 2024, 15:28 UTC

Market Talk

Câștiguri

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30 iul. 2024, 13:45 UTC

Câștiguri

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30 iul. 2024, 10:45 UTC

Câștiguri

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30 iul. 2024, 10:32 UTC

Câștiguri

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30 iul. 2024, 10:31 UTC

Câștiguri

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30 iul. 2024, 10:31 UTC

Câștiguri

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Keytruda Sales Up 16% >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Keytruda Sales $7.27B >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Januvia/Janumet Sales Down 27% >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Net $5.46B >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Januvia/Janumet Sales $629M >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Pharmaceutical Sales Up 7% >MRK

30 iul. 2024, 10:30 UTC

Câștiguri

Merck 2Q Gardasil/Gardasil 9 Sales $2.48B >MRK

30 iul. 2024, 08:38 UTC

Top știri

These Stocks Are Moving the Most Today: Microsoft, CrowdStrike, F5, Lattice Semiconductor, BP, Tilray, and More -- Barrons.com

28 iul. 2024, 23:02 UTC

Top știri

Stocks Poised for Higher Open -- Barrons.com

12 iul. 2024, 10:45 UTC

Achiziții, Fuziuni, Preluări

Merck to Post 3Q Charge of About $1.3 Billion, or 50c/Share, on EyeBio Deal >MRK

12 iul. 2024, 10:45 UTC

Achiziții, Fuziuni, Preluări

Merck Completes Acquisition Of EyeBio >MRK

9 iul. 2024, 12:30 UTC

Achiziții, Fuziuni, Preluări

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 iul. 2024, 12:29 UTC

Achiziții, Fuziuni, Preluări

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

Comparație

Modificare preț

Merck & Co Inc. Așteptări

Obiectiv de preț

By TipRanks

18.88% sus

Prognoză pe 12 luni

Medie 140.09 USD 18.88%

Maxim 155 USD

Minim 125 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMerck & Co Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 16 analiști care au acordat evaluări ale acțiunilor Merck & Co Inc. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

116.6 / 118.395Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.